Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Vaxneuvance Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The expansion observed historically can be linked to the broader implementation of routine pneumococcal vaccination programs, a rising number of pneumococcal infections, greater recognition of vaccine-preventable diseases, advancements in conjugate vaccine science, and improved access to healthcare.
The projected growth during the forecast period can be attributed to escalating investments in next-generation vaccines, a heightened focus on immunizing the elderly, the expansion of national vaccination initiatives, an increasing demand for higher-valency vaccines, and their growing adoption within emerging healthcare systems. Key trends anticipated in this period include the wider acceptance of broad-spectrum pneumococcal vaccines, an intensified emphasis on preventing invasive diseases, the expanding coverage of pediatric and adult immunizations, advancements in conjugate vaccine technologies, and a stronger commitment to protecting high-risk populations.
Get A Free Sample Report With In-Depth Market Insights:
Vaxneuvance Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
The widespread occurrence of pneumonia is anticipated to fuel the expansion of the vaxneuvance market in the future. Pneumonia is characterized as an infection leading to inflammation within the air sacs of one or both lungs, often filling with fluid or pus, which manifests as symptoms like coughing, fever, and breathing challenges. Several factors contribute to the prevalence of pneumonia, including viral and bacterial pathogens, diminished immune systems, atmospheric pollution, and an expanding elderly demographic, all of which heighten individuals’ vulnerability to respiratory ailments. Vaxneuvance assists patients by offering protection against pneumonia instigated by 15 strains of Streptococcus pneumoniae, thereby mitigating the danger of serious infections and associated complications. For instance, in 2024, as per the Johns Hopkins University, a US-based research university, the mean Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score observed across 15 countries was 56%, indicating an increase of 2% from 54% recorded in 2023. Consequently, the significant prevalence of pneumonia is driving the growth of the vaxneuvance market.
Vaxneuvance Market Segment Landscape And Growth Outlook
The vaxneuvance market covered in this report is segmented –
1) By Indication: Pneumonia, Meningitis, Sepsis, Bacteremia, Otitis Media
2) By Distribution Channel: Pharmacies, Hospitals
3) By End User: Adults, Children, Geriatric Population
Vaxneuvance Market Innovation Trends Shaping Future Development
Leading enterprises within the vaxneuvance (pneumococcal conjugate vaccine) market are concentrating on creating innovative solutions, specifically next-generation multivalent conjugate vaccines, aimed at offering expanded defense against pneumococcal infections. These advanced vaccines, known as next-generation multivalent conjugate vaccines, are formulated to safeguard against numerous strains of a pathogen through the connection of polysaccharides from each strain to a carrier protein, thereby boosting the immune response. An illustrative example occurred in May 2025, when Vietnam Vaccine JSC (VNVC), a US-based corporation, unveiled the pneumococcal 15-valent conjugate vaccine (PCV15 or Vaxneuvance), intended to broaden protection against various strains of Streptococcus pneumoniae implicated in both invasive and non-invasive illnesses. This vaccine is indicated for children from six weeks of age and adults, providing enduring immunity and contributing to the reduction of pneumococcal bacteria transmission within the population. The introduction of this vaccine places VNVC prominently in modern pneumococcal vaccination in Vietnam, supplementing its current range of pneumococcal vaccines and reinforcing national immunization programs.
Vaxneuvance Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the vaxneuvance market are Merck & Co. Inc.
View The Full Vaxneuvance Market Report:
Vaxneuvance Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the vaxneuvance market in 2025. The regions covered in the vaxneuvance market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model